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Mariana Toricelli1, Fabiana H. M. Melo1,2, Giovani B. Peres3, Débora C. P. Silva4 and Miriam G. Jasiulionis1*Erratum
After publication of this study [1], we found out that
we unfortunately sent two figures in duplicate. They
are Fig. 4b NT and Fig. 6c NT [1]. It is important to
emphasize that the results shown in the graphs are correct
since they represent the mean of three independent bio-
logical assays, each of them made in technical triplicates.
The photographs are only representative figures of three
biological assays.
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Fig. 4 PI3-K signaling pathway is involved in anoikis resistance phenotype conferred by Timp1. The MaGFP and MaT1S cell lines were treated
overnight with PI3-K inhibitors, Wortmannin (a) or LY294002 (b), and their clonogenic capability was evaluated. c Melan-a melanocytes stably
transfected with GFP (control transfection, MaGFP) and Timp1 (MaT1S) were maintained in suspension for 1, 3, 5 and 24 hours. The Akt activation
was assessed by Western blotting. *p < 0.05, **p < 0.01, ****p < 0.0001
Fig. 6 PI3-K inhibition renders melanoma cells anoikis sensitive. The 4C11- and 4C11+ melanoma cell lines were maintained in suspension for 96
hours in the presence of Wortmannin (a and b, respectively) or LY294002 (c and d, respectively). After 96 hours, suspended cells were plated and
after 5 days clonogenic capacity was analyzed. 4C11-: non-metastatic melanoma cells; 4C11+: metastatic melanoma cells; NT: non-treated; Wn:
Wortmannin; LY: LY294002. *p < 0.05, **p < 0.01, ***p < 0.001
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